To identify whether SH3BP1 and downstream Rac1 signaling are involved in drug sensitivity in CML, we investigated the role of SH3BP1 and Rac1 in nilotinib resistance using the K562 cell line. The gene discussed is RAC1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.